Covid-19 Antiviral Medication
Adult patients testing positive for SARS-CoV-2 (Covid-19) who are at increased risk of complications from Covid-19 infection may be appropriate for antiviral medication.
Qualifying conditions include:
• Down’s Syndrome
• Patients with liver disease
• Sickle Cell Disease
• Primary immune deficiencies
• Patients with a solid cancer
• Patients with a haematologic malignancy
• Solid organ transplant recipients
• Patients with renal disease (CKD 4/5)
• Patients with Immune-mediated inflammatory disorders (IMID)
• Rare neurological conditions
More detailed information is available here: 5 Supporting information on risk factors for progression to severe COVID-19 | Casirivimab plus imdevimab, nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19 | Guidance | NICE
Assessment for eligibility of Covid-19 antiviral medication is provided by the Covid Medicines Delivery Unit (CMDU).
CMDU will also arrange for the supply of oral medication or intravenous infusions as required. CMDU can only deal with patients who have mild & moderate symptoms. Patients with severe symptoms (including those requiring supplemental oxygen) may require hospital admission.
To refer an adult patient that you consider eligible, please complete the referral form below and send to email@example.com
Please note that this service is not contactable by telephone.
This service operates Mon – Fri excluding bank holidays. Referrers will be sent notification of the CMDU outcome.
Eligible paediatric patients (0-17 years) testing positive for Covid-19 should be referred to the on call paediatric team for an MDT assessment to determine treatment options.